Non-HLA antigens in health, aging, and malignancy : proceedings of a conference held at Roswell Park Memorial Institute, Buffalo, New York, March 28 and 29, 1983 / editors, Elias Cohen, Dharam P. Singal.

Date:
[1983], ©1983
Catalogue details

Licence: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Credit: Non-HLA antigens in health, aging, and malignancy : proceedings of a conference held at Roswell Park Memorial Institute, Buffalo, New York, March 28 and 29, 1983 / editors, Elias Cohen, Dharam P. Singal. Source: Wellcome Collection.

    285/296 (page 261)
    Index / 261 Listeria monocytogenes, 101 Longevity and immunogenetics, 11-%Ь\ see also Aging Lupus, 37 Lutheran system, 54 Lymphocyte(s) -bacterial binding and aging, 95-99, 101- 104 leukemic B, antigens, 135-142 mixed culture (MLC), 3, 4 primed, test. See Primed lymphocyte test T. See T cells (lymphocytes) Lymphoma Burkitt's, 215, 219, 221 non-Hodgkin's (T and В cell), 157 anti-T antibody reactivity, 183-187 determination of clonal excess, 197-202 diagnosis of minimal disease, 202 histiocytic, 197 immunoglobulins, heavy and light chain, 197-202 in remission, 198 plasma membrane, DPP IV, 191-195 T cell leukemia/lymphoma, 191-195 Lymphosarcoma 6C3HED, 245, 246 Macroglobulin, Waldenstrom, 194 Major histocompatibility complex (MHC), 3 and aging, 77, 82-83, 85 co-recognition of foreign antigens, 11 Malignant melanoma. See Melanoma, malignant Mammary adenocarcinoma, rat, metastasizing and nonmetastasizing antigenic characteristics, 227-233 ascites fluid, 228-229, 231-232 MT-100, 227-233 SDS-PAGE, 228, 229 TMT-081, 227-233 tumor associated antigens, 116-119 see also Breast cancer Markers, pancreatic tumor, 168, 169 Melanocarcinoma, 163 Melanoma, malignant -specific oncofetal antigen gp87, 125-133 biosynthetic profiles, 129-131 inhibition of glycosylation, 132 molecular characteristics, 127-128 monoclonal antibody (140.20), 125-133 shedding, 132 tryptic peptide mapping, 131-132 surface antigens and HLA antigens, 203-204, 206 mixed hemadsorption assay, 204 monoclonal antibodies 140.72 and 140.240, 203-207 selective release following 1-butanol treatment, 203-207 Membrane(s) glycoproteins, and platelet autoantigens, 31, 36-39 immunoglobulin, 135 plasma leukemia/lymphoma, DPP IV, 191- 195 platelet glycoproteins, 35-36 Method. See Technique /З-2-Microglobulin, 16-17 Mixed lymphocyte culture (MLC), 3, 4 MN system, 54-55, 158, 163 MO/NK cell. See Cell(s), MO/NK Monoclonal antibodies to alloantigen-activated human T lymphocyte surface antigen (MoAb69), 47-51 Ba-2, 137, 140 B72.3, breast cancer, 115-123 for characterization of human myelomonocytic antigens, 145-154 in diagnosis of CML, 145-154 DU-HL60-1,3,4, 146-164 reactivity with leukemic cells, 150-154 reactivity with nonlymphoid tissue, 151 SDS-PAGE, 147, 154 Leu, 135-142, 183-187 L227, 19 to melanoma antigens (140.72, 140.240, oncofetal gp87), 125-133, 203-207 MoAb 557 and 601, 48, 50-51 OKT, 135-142, 183-187, 217 in AIDS and KS, 211-212 3,4,8,10, 90-93 to T and Tn system antigens, 160 T-101, 135 Monocyte(s) antigens, 18-20 VEL/, 255 see also Cell(s), MO/NK Monocytotoxic antibody and graft rejection, 254-255